Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Shareholders' (Deficit) Equity (Unaudited)

v3.23.3
Consolidated Statements of Shareholders' (Deficit) Equity (Unaudited) - USD ($)
$ in Thousands
Total
Registered Direct Offerings
Public Offerings
Equity Line Of Credit
Preferred Stock
Common Stock
Common Stock
Registered Direct Offerings
Common Stock
Public Offerings
Common Stock
Equity Line Of Credit
Additional Paid in Capital
Additional Paid in Capital
Registered Direct Offerings
Additional Paid in Capital
Public Offerings
Additional Paid in Capital
Equity Line Of Credit
Accumulated Deficit
Series X Convertible Preferred Stock [Member]
Series X Convertible Preferred Stock [Member]
TeraImmune [Member]
Balance at Dec. 31, 2021 $ 13,226       $ 0 $ 1       $ 145,314       $ (132,089)    
Balance, Shares at Dec. 31, 2021         8,289 70,181                    
Stock-based compensation expense 521                 521            
Issuance of common stock   $ (13) $ 8,818         $ 1     $ (13) $ 8,817        
Stock Issued During Period, Shares, New Issues               87,719                
Issuance of preferred stock   (13) 8,818         $ 1     (13) 8,817        
Issuance of preferred stock upon acquisition of Teralmmune               87,719                
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes, Shares           56                    
Conversion of preferred stock         (8,289) 2,368                    
Net income (loss) (12,809)                         (12,809)    
Balance at Mar. 31, 2022 9,743       $ 0 $ 2       154,639       (144,898)    
Balance, Shares at Mar. 31, 2022         0 160,324                    
Balance at Dec. 31, 2021 13,226       $ 0 $ 1       145,314       (132,089)    
Balance, Shares at Dec. 31, 2021         8,289 70,181                    
Net income (loss) (49,546)                              
Balance at Sep. 30, 2022 (24,171)       $ 0 $ 2       157,483       (181,656)    
Balance, Shares at Sep. 30, 2022         20,004 206,010                    
Balance at Mar. 31, 2022 9,743       $ 0 $ 2       154,639       (144,898)    
Balance, Shares at Mar. 31, 2022         0 160,324                    
Stock-based compensation expense 325                 325            
Issuance of common stock   1,720 (28)               1,720 (28)        
Stock Issued During Period, Shares, New Issues             41,152                  
Issuance of preferred stock   1,720 (28)               1,720 (28)        
Issuance of preferred stock upon acquisition of Teralmmune             41,152                  
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes, Shares           245                    
Net income (loss) (7,531)                         (7,531)    
Balance at Jun. 30, 2022 4,229       $ 0 $ 2       156,656       (152,429)    
Balance, Shares at Jun. 30, 2022         0 201,721                    
Stock-based compensation expense 874                 874            
Issuance of common stock   (38)                 (38)          
Issuance of preferred stock   (38)                 (38)          
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes (29)                 (29)            
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes, Shares           4,289                    
Stock Dividend shares         20,004                      
Stock dividend                   20       (20)    
Net income (loss) (29,207)                         (29,207)    
Balance at Sep. 30, 2022 (24,171)       $ 0 $ 2       157,483       (181,656)    
Balance, Shares at Sep. 30, 2022         20,004 206,010                    
Balance at Dec. 31, 2022 (24,242)       $ 0 $ 16       166,646       (190,904) $ 0  
Balance, Shares at Dec. 31, 2022         0 1,623,913                 0  
Stock-based compensation expense 194                 194            
Issuance of common stock     (55)                 (55)        
Issuance of preferred stock     (55)                 (55)        
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes, Shares           2                    
Exercise of warrants 4,328         $ 10       4,318            
Exercise of warrants, Shares           961,787                    
Issuance of warrants for MAM debt amendment 1,058                 1,058            
Net income (loss) 11,404                         11,404    
Balance at Mar. 31, 2023 (7,313)       $ 0 $ 26       172,161       (179,500) $ 0  
Balance, Shares at Mar. 31, 2023         0 2,585,702                 0  
Balance at Dec. 31, 2022 (24,242)       $ 0 $ 16       166,646       (190,904) $ 0  
Balance, Shares at Dec. 31, 2022         0 1,623,913                 0  
Net income (loss) 2,095                              
Balance at Sep. 30, 2023 (10,238)       $ 0 $ 122       178,940       (189,300) $ 9,040  
Balance, Shares at Sep. 30, 2023         36,267 12,164,753                 20,066  
Balance at Mar. 31, 2023 (7,313)       $ 0 $ 26       172,161       (179,500) $ 0  
Balance, Shares at Mar. 31, 2023         0 2,585,702                 0  
Stock-based compensation expense 208                 208            
Issuance of common stock 544   3,257     $ 9   $ 35   535   3,222       $ 9,040
Stock Issued During Period, Shares, New Issues           897,903   3,478,262               20,066
Issuance of preferred stock 544   $ 3,257     $ 9   $ 35   535   $ 3,222       $ 9,040
Issuance of preferred stock upon acquisition of Teralmmune           897,903   3,478,262               20,066
Net income (loss) (7,375)                         (7,375)    
Balance at Jun. 30, 2023 (10,679)       $ 0 $ 70       176,126       (186,875) $ 9,040  
Balance, Shares at Jun. 30, 2023         0 6,961,867                 20,066  
Stock-based compensation expense 253                 253            
Issuance of common stock   1,611   $ 511     $ 34   $ 18   1,577   $ 493      
Stock Issued During Period, Shares, New Issues             3,401,787   1,794,170              
Issuance of preferred stock   $ 1,611   $ 511     $ 34   $ 18   $ 1,577   $ 493      
Issuance of preferred stock upon acquisition of Teralmmune             3,401,787   1,794,170              
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes, Shares           6,929                    
Stock Dividend shares         36,267                      
Stock dividend                   36       (36)    
Net income (loss) (1,934)                         (1,934)    
Balance at Sep. 30, 2023 $ (10,238)       $ 0 $ 122       $ 178,940       $ (189,300) $ 9,040  
Balance, Shares at Sep. 30, 2023         36,267 12,164,753                 20,066